MCM
NBIX icon

MAI Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

MAI Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Buy
8,096
+3,854
+91% +$572K 0.01% 845
2026
Q1 		$559K Buy
4,242
+3,814
+891% +$506K ﹤0.01% 982
2025
Q4 		$60.7K Buy
428
+301
+237% +$43.6K ﹤0.01% 1901
2025
Q3 		$17.8K Sell
127
-201
-61% -$27.2K ﹤0.01% 2457
2025
Q2 		$41.2K Buy
328
+165
+101% +$18.9K ﹤0.01% 1972
2025
Q1 		$18K Sell
163
-117
-42% -$14.8K ﹤0.01% 2231
2024
Q4 		$38.2K Buy
+280
New +$34.6K ﹤0.01% 1893
2022
Q3 		– Sell
-6,412
Closed -$625K – 1009
2022
Q2 		$625K Hold
6,412
– – 0.01% 486
2022
Q1 		$601K Buy
6,412
+745
+13% +$63.1K 0.01% 510
2021
Q4 		$483K Buy
5,667
+355
+7% +$32.7K 0.01% 588
2021
Q3 		$509K Buy
5,312
+171
+3% +$16.2K 0.01% 509
2021
Q2 		$500K Sell
5,141
-2
-0% -$192 0.01% 491
2021
Q1 		$500K Buy
5,143
+762
+17% +$79.9K 0.01% 475
2020
Q4 		$420K Sell
4,381
-1,075
-20% -$104K 0.01% 482
2020
Q3 		$525K Buy
+5,456
New +$631K 0.02% 391

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MAI Capital Management's NBIX Position: Q2 2026 in Review

MAI Capital Management increased its Neurocrine Biosciences (NBIX) stake by 91% in Q2 2026, buying an estimated $572K and bringing the position to 8,096 shares worth $1.36M. The position accounts for 0.01% of the portfolio, ranked #845.

MAI Capital Management first reported a position in NBIX in Q3 2020 and has held it in 15 quarters since. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • MAI Capital Management held 8,096 shares of Neurocrine Biosciences worth $1.36M as of Q2 2026.
  • MAI Capital Management bought 3,854 Neurocrine Biosciences shares in Q2 2026, an estimated $572K.
  • Neurocrine Biosciences made up 0.01% of MAI Capital Management's portfolio in Q2 2026, its #845 holding.
  • MAI Capital Management first reported a position in Neurocrine Biosciences in Q3 2020 and has held it in 15 quarters since.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.